Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
10 August 2017Website:
http://www.dermtech.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
DMTK Latest News
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DM.
DermTech, Inc. (DMTK) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.93 per share a year ago.
DermTech, Inc. (NASDAQ:DMTK ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head, Investor Relations Bret Christensen - President & Chief Executive Officer Kevin Sun - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to DermTech's Second Quarter 2023 Financial Results Call.
Nano-X is marketing a different type of X-ray system. DermTech's Smart Sticker system could change dermatology.
What type of business is DermTech?
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
What sector is DermTech in?
DermTech is in the Healthcare sector
What industry is DermTech in?
DermTech is in the Diagnostics & Research industry
What country is DermTech from?
DermTech is headquartered in United States
When did DermTech go public?
DermTech initial public offering (IPO) was on 10 August 2017
What is DermTech website?
https://www.dermtech.com
Is DermTech in the S&P 500?
No, DermTech is not included in the S&P 500 index
Is DermTech in the NASDAQ 100?
No, DermTech is not included in the NASDAQ 100 index
Is DermTech in the Dow Jones?
No, DermTech is not included in the Dow Jones index
When does DermTech report earnings?
The next expected earnings date for DermTech is 02 August 2024